Maintenance ZD1839 (IRESSA®) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (IMAC/Herbst)
2013年1月28日 更新者:AstraZeneca
A Phase IIIb Randomized, Double-Blind Study Comparing Maintenance ZD1839 (IRESSA®) or Placebo Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer
In this Phase IIIb, randomized, double-blind, maintenance study, 300 subjects with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) (Stage IIIB {T4-pleural effusion} and IV) who have SD or objective tumor response immediately following the completion of 4-6 cycles of front line, platinum-based, doublet chemotherapy will be randomized in a double-blind manner to receive either ZD1839 or placebo.
研究概览
研究类型
介入性
阶段
- 第三阶段
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 及以上 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria:
- Must sign Informed Consent
- Females and males aged 18 years and over.
- Confirmed stage IIIB (T4-pleural effusion) and IV NSCLC.
- Either complete response, partial response, or stable disease following at least 4 cycles (3 in the setting of intolerable toxicity) but no more than 6 cycles of definitive front line, platinum-based, doublet chemotherapy.
- No prior EGFR therapy
- No newly diagnosed intracerebral metastases while receiving or after completing chemotherapy
- At least 3 weeks (21 days) but no more than 4 weeks (28 days) since last dose of chemotherapy
- Must be completely healed from previous major oncologic surgery
- Life expectancy of ≥ 8 weeks.
Exclusion Criteria:
- Known severe hypersensitivity to ZD1839 or any of the excipients of these products.
- Any evidence of clinically active interstitial lung disease (subjects with chronic, stable, radiographic changes who are asymptomatic need not be excluded).
- Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ.
- Any unresolved chronic toxicity greater than common toxicity criteria (CTC) grade 2 from previous anticancer therapy excluding peripheral neuropathy or alopecia.
- Evidence of any significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the study.
- Pregnancy or breast feeding (women of child bearing potential). Women of childbearing potential must practice acceptable methods of birth control to prevent pregnancy.
- Treatment with a non-approved or investigational drug within 30 days before Day 1 of study treatment.
- Signs of neurological symptoms consistent with new onset spinal cord compression or CNS metastases.
- Treatment with any systemic anticancer therapies other than the prescribed protocol chemotherapy regimen (refer to Inclusion criterion -). Exception: Palliative radiotherapy for symptom relief of lesions present at diagnosis will be allowed; however, this radiotherapy must occur prior to completion of pre-study doublet chemotherapy.
- Males must also be willing to practice acceptable methods of birth control while taking the drug to prevent pregnancy of a partner.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 屏蔽:双倍的
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
赞助
调查人员
- 研究主任:Iressa Medical Science Director、AstraZeneca
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2006年1月1日
初级完成 (预期的)
2007年11月1日
研究完成 (预期的)
2007年11月1日
研究注册日期
首次提交
2004年9月2日
首先提交符合 QC 标准的
2004年9月2日
首次发布 (估计)
2004年9月3日
研究记录更新
最后更新发布 (估计)
2013年1月29日
上次提交的符合 QC 标准的更新
2013年1月28日
最后验证
2013年1月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.